Reports Q2 revenue $356.679M. "Our strong fiscal second quarter results show the expansion and strength of our global portfolio, which now includes operations in the United Kingdom, United States and Australia," commented Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions. "We continued to bolster Intelligent Bio Solution’s leadership position in the field of non-invasive real-time diagnostic testing in the second quarter, achieving several significant strategic goals. We released the successful results from Milestone 7, which showed a four-time improvement in time-to-result for our biosensor platform, returning test results in less than a minute. These exciting results were a green light for our biosensor development team to progress to the next testing phase, which will include testing human saliva."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INBS:
- Intelligent Bio Solutions Inc. Reports Fiscal 2023 Second Quarter Financial Results and Operational Highlights
- Intelligent Bio Solutions Inc. Announces Reverse Stock Split
- Intelligent Bio Solutions Inc. Announces Leading Food Industry Logistics Provider to Implement Fingerprint Drug Testing, Replacing Urine Testing
- Intelligent Bio Solutions Inc. Announces Global Garden Equipment Manufacturer to Introduce Intelligent Fingerprinting Drug Tests
- Intelligent Bio Solutions Reaches Key Milestone in Biosensor Platform Development